The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IMS 2024 | The real-world safety & efficacy of talquetamab in patients with heavily pretreated R/R myeloma
Bruno Costa, MD, Icahn School of Medicine at Mount Sinai, New York, NY, discusses the real-world efficacy and safety of talquetamab, a GPRC5D-directed bispecific antibody, in patients with relapsed/refractory (R/R) multiple myeloma (MM) with at least four prior lines of therapy. In a retrospective cohort of 28 heavily pretreated patients, including a significant proportion who would not have met the eligibility criteria for the pivotal MonumenTAL-1 trial (NCT04634552), an overall response rate (ORR) of 62% was observed, along with a manageable safety profile. This interview took place at the 21st International Myeloma Society (IMS) Annual Meeting, held in Rio de Janeiro, Brazil.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
